NASDAQ:LGND

Ligand Pharmaceuticals Stock Forecast, Price & News

$118.96
-4.49 (-3.64 %)
(As of 07/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$118.26
$125.54
50-Day Range
$113.03
$139.37
52-Week Range
$78.26
$219.75
Volume202,646 shs
Average Volume347,159 shs
Market Capitalization$1.98 billion
P/E Ratio51.72
Dividend YieldN/A
Beta1.18
30 days | 90 days | 365 days | Advanced Chart
Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Ligand Pharmaceuticals logo

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

632nd out of 2,214 stocks

Pharmaceutical Preparations Industry

324th out of 869 stocks

Analyst Opinion: 3.4Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

Is Ligand Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ligand Pharmaceuticals stock.
View analyst ratings for Ligand Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ligand Pharmaceuticals?

Wall Street analysts have given Ligand Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ligand Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Ligand Pharmaceuticals
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings results on Sunday, May, 2nd. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.13 by $0.28. The biotechnology company earned $55.10 million during the quarter, compared to the consensus estimate of $63 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 8.50% and a net margin of 18.83%. The firm's revenue for the quarter was up 66.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 EPS.
View Ligand Pharmaceuticals' earnings history
.

How has Ligand Pharmaceuticals' stock been impacted by Coronavirus?

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, LGND stock has increased by 29.5% and is now trading at $118.96.
View which stocks have been most impacted by COVID-19
.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, July, 29th. The company provided earnings per share guidance of $5.800-$6.050 for the period, compared to the Thomson Reuters consensus estimate of $6.120. The company issued revenue guidance of $265 million-$275 million, compared to the consensus revenue estimate of $280.44 million.

What price target have analysts set for LGND?

6 Wall Street analysts have issued 1 year target prices for Ligand Pharmaceuticals' shares. Their forecasts range from $190.00 to $310.00. On average, they anticipate Ligand Pharmaceuticals' share price to reach $228.75 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the following people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 51, Pay $1.18M)
  • Mr. Matthew W. Foehr, Pres & COO (Age 48, Pay $938.81k)
  • Mr. Matthew E. Korenberg, Exec. VP of Fin. & CFO (Age 46, Pay $754.09k)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 52, Pay $624.86k)
  • Patrick O'Brien, Sr. VP of Investor Relations
  • Mr. Todd Pettingill, Director of Corp. Devel.
  • Ms. Audrey Warfield-Graham, Sr. VP of HR
  • Dr. Keith Marschke, Sr. VP of Biology & Scientific Affairs
  • Dr. Vincent D. Antle, Sr. VP of Technical Operations & QA - Capitsol (Age 52)
  • Mr. Patrick Lucy, Sr. VP & CBO Protein Expression Bus.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals CEO John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among Ligand Pharmaceuticals' employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Ligand Pharmaceuticals' key competitors?

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.03%) and New Mexico Educational Retirement Board (0.02%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, Matthew W Foehr, Sunil Patel and Todd C Davis.
View institutional ownership trends for Ligand Pharmaceuticals
.

Which institutional investors are buying Ligand Pharmaceuticals stock?

LGND stock was bought by a variety of institutional investors in the last quarter, including New Mexico Educational Retirement Board, and Oregon Public Employees Retirement Fund. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins, Matthew W Foehr, and Sunil Patel.
View insider buying and selling activity for Ligand Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $118.96.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals has a market capitalization of $1.98 billion and generates $186.42 million in revenue each year. The biotechnology company earns $-2,980,000.00 in net income (profit) each year or $3.13 on an earnings per share basis.

How many employees does Ligand Pharmaceuticals have?

Ligand Pharmaceuticals employs 155 workers across the globe.

What is Ligand Pharmaceuticals' official website?

The official website for Ligand Pharmaceuticals is www.ligand.com.

Where are Ligand Pharmaceuticals' headquarters?

Ligand Pharmaceuticals is headquartered at 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.